266 related articles for article (PubMed ID: 28233107)
1. Management of small T1a/b breast cancer by tumor subtype.
Ignatov T; Eggemann H; Burger E; Costa SD; Ignatov A
Breast Cancer Res Treat; 2017 May; 163(1):111-118. PubMed ID: 28233107
[TBL] [Abstract][Full Text] [Related]
2. [Clinicopathological characteristics and prognosis of different molecular types of breast cancer].
Liu ZF; Chen C; Yao XL; Sun SR
Zhonghua Yi Xue Za Zhi; 2016 Jun; 96(22):1733-7. PubMed ID: 27356638
[TBL] [Abstract][Full Text] [Related]
3. Histological grade provides significant prognostic information in addition to breast cancer subtypes defined according to St Gallen 2013.
Ehinger A; Malmström P; Bendahl PO; Elston CW; Falck AK; Forsare C; Grabau D; Rydén L; Stål O; Fernö M;
Acta Oncol; 2017 Jan; 56(1):68-74. PubMed ID: 27762648
[TBL] [Abstract][Full Text] [Related]
4. [Clinical features and prognosis of patients with first-episode liver metastasis of different molecular subtypes of breast cancer].
Wu SY; Tan Y; Guan YS
Zhonghua Gan Zang Bing Za Zhi; 2016 Jun; 24(6):422-8. PubMed ID: 27465945
[TBL] [Abstract][Full Text] [Related]
5. Characteristics and outcomes according to molecular subtypes of breast cancer as classified by a panel of four biomarkers using immunohistochemistry.
Park S; Koo JS; Kim MS; Park HS; Lee JS; Lee JS; Kim SI; Park BW
Breast; 2012 Feb; 21(1):50-7. PubMed ID: 21865043
[TBL] [Abstract][Full Text] [Related]
6. Impact of age, intrinsic subtype and local treatment on long-term local-regional recurrence and breast cancer mortality among low-risk breast cancer patients.
Laurberg T; Alsner J; Tramm T; Jensen V; Lyngholm CD; Christiansen PM; Overgaard J
Acta Oncol; 2017 Jan; 56(1):59-67. PubMed ID: 27846764
[TBL] [Abstract][Full Text] [Related]
7. Prognosis in women with small (T1mic,T1a,T1b) node-negative operable breast cancer by immunohistochemically selected subtypes.
Cancello G; Maisonneuve P; Rotmensz N; Viale G; Mastropasqua MG; Pruneri G; Montagna E; Dellapasqua S; Iorfida M; Cardillo A; Veronesi P; Luini A; Intra M; Gentilini O; Scarano E; Goldhirsch A; Colleoni M
Breast Cancer Res Treat; 2011 Jun; 127(3):713-20. PubMed ID: 21452022
[TBL] [Abstract][Full Text] [Related]
8. Prognostic value of circulating tumor cells according to immunohistochemically defined molecular subtypes in advanced breast cancer.
Munzone E; Botteri E; Sandri MT; Esposito A; Adamoli L; Zorzino L; Sciandivasci A; Cassatella MC; Rotmensz N; Aurilio G; Curigliano G; Goldhirsch A; Nolè F
Clin Breast Cancer; 2012 Oct; 12(5):340-6. PubMed ID: 23040002
[TBL] [Abstract][Full Text] [Related]
9. Molecular subtype predicts incidence and prognosis of brain metastasis from breast cancer in SEER database.
Kim YJ; Kim JS; Kim IA
J Cancer Res Clin Oncol; 2018 Sep; 144(9):1803-1816. PubMed ID: 29971531
[TBL] [Abstract][Full Text] [Related]
10. Descriptive analysis of molecular subtypes in Tunisian breast cancer.
Fourati A; Boussen H; El May MV; Goucha A; Dabbabi B; Gamoudi A; Sfar R; Rahal K; El May A; Ben Abdallah M
Asia Pac J Clin Oncol; 2014 Jun; 10(2):e69-74. PubMed ID: 23176549
[TBL] [Abstract][Full Text] [Related]
11. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
[TBL] [Abstract][Full Text] [Related]
12. The effect of trastuzumab-based chemotherapy in small node-negative HER2-positive breast cancer.
van Ramshorst MS; van der Heiden-van der Loo M; Dackus GM; Linn SC; Sonke GS
Breast Cancer Res Treat; 2016 Jul; 158(2):361-71. PubMed ID: 27357813
[TBL] [Abstract][Full Text] [Related]
13. Prognostic significance of the progesterone receptor status in Ki67-high and -low Luminal B-like HER2-negative breast cancers.
Sato K; Miyashita M; Ishida T; Suzuki A; Tada H; Watanabe G; Sato-Tadano A; Watanabe M; Ohuchi N
Breast Cancer; 2016 Mar; 23(2):310-7. PubMed ID: 25380989
[TBL] [Abstract][Full Text] [Related]
14. Triple-negative phenotype is of adverse prognostic value in patients treated with dose-dense sequential adjuvant chemotherapy: a translational research analysis in the context of a Hellenic Cooperative Oncology Group (HeCOG) randomized phase III trial.
Skarlos P; Christodoulou C; Kalogeras KT; Eleftheraki AG; Bobos M; Batistatou A; Valavanis C; Tzaida O; Timotheadou E; Kronenwett R; Wirtz RM; Kostopoulos I; Televantou D; Koutselini E; Papaspirou I; Papadimitriou CA; Pectasides D; Gogas H; Aravantinos G; Pavlidis N; Arapantoni P; Skarlos DV; Fountzilas G
Cancer Chemother Pharmacol; 2012 Feb; 69(2):533-46. PubMed ID: 21901395
[TBL] [Abstract][Full Text] [Related]
15. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
[TBL] [Abstract][Full Text] [Related]
16. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
[TBL] [Abstract][Full Text] [Related]
17. Triple negative breast cancer in Korea-distinct biology with different impact of prognostic factors on survival.
Lee JA; Kim KI; Bae JW; Jung YH; An H; Lee ES;
Breast Cancer Res Treat; 2010 Aug; 123(1):177-87. PubMed ID: 20574671
[TBL] [Abstract][Full Text] [Related]
18. [Clinical characteristics and survival in the operable breast cancer patients with different molecular subtypes].
Zhang HM; Zhang BN; Xuan LX; Zhao P
Zhonghua Zhong Liu Za Zhi; 2009 Jun; 31(6):447-51. PubMed ID: 19950556
[TBL] [Abstract][Full Text] [Related]
19. Is biological subtype prognostic of locoregional recurrence risk in women with pT1-2N0 breast cancer treated with mastectomy?
Truong PT; Sadek BT; Lesperance MF; Alexander CS; Shenouda M; Raad RA; Taghian AG
Int J Radiat Oncol Biol Phys; 2014 Jan; 88(1):57-64. PubMed ID: 24161421
[TBL] [Abstract][Full Text] [Related]
20. Evaluation of clinical parameters influencing the development of bone metastasis in breast cancer.
Diessner J; Wischnewsky M; Stüber T; Stein R; Krockenberger M; Häusler S; Janni W; Kreienberg R; Blettner M; Schwentner L; Wöckel A; Bartmann C
BMC Cancer; 2016 May; 16():307. PubMed ID: 27175930
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
